Study Title
LTS16294: A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A
Protocol ID
LTS16294
Disease (Sub Disease)
Hemophilia A
Diagnosis Stage
Previously treated
Location
NSW, QLD, WA
Sponsor
Bioverativ, a Sanofi company
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Children's Hospital at Westmead
Sydney Children's Hospital
Perth Children's Hospital
Children's Hospital at Westmead
Sydney Children's Hospital
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
Child, Adult, Older Adult
International registry ID's
NCT04644575
| Study Title | LTS16294: A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A |
|---|---|
| Protocol ID | LTS16294 |
| Disease (Sub Disease) | Hemophilia A |
| Diagnosis Stage | Previously treated |
| Location | NSW / QLD / WA |
| Sponsor | Bioverativ, a Sanofi company/ |
| Links | https://clinicaltrials.gov/ct2/show/NCT04644575 |
| Trial Status | Open |
| Trial Open Date | 23/02/2022 |
| Sites | Queensland Children's Hospital / Children's Hospital at Westmead/ Sydney Children's Hospital/ Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | Child, Adult, Older Adult |
| International registry ID's | NCT04644575 |